27 October 2021

Tekcapital Plc

("Tekcapital", the "Company" or "the Group")

Portfolio Company Update: Salarius, Ltd. ("Salarius")

Appointment of Dr. Jay Shah as Chief Medical Officer

Tekcapital Plc (AIM: TEK), (OTCQB: TEKCF) the UK intellectual property investment group focused on creating valuable products from investing in university technology that can improve people's lives, is very pleased to announce that Dr. Jay Shah has been appointed as Chief Medical Officer for MicroSalt®. Previously, Dr. Shah served as a medical advisor to the Company.

Dr. Shah is a seasoned leader with over 15 years of progressive and diverse experiences in the medical field within academic, clinical, and teaching environments, as well as building medical businesses and service lines. He is currently a cardiologist at the Mayo Clinic and an Assistant Professor at the Mayo Clinic School of Medicine.

While practicing at the Mayo Clinic he built a comprehensive, multidisciplinary programme of care for thoracic aortic diseases. Previously, Dr. Shah completed his internal medicine residency at Massachusetts General Hospital in 2009 and

the Cardiovascular Disease Fellowship Program at Washington University School of Medicine In 2012.

"I am very pleased to serve as Chief Medical Officer for MicroSalt®. Their goal is to provide a better salt, that reduces excess sodium consumption, a major risk factor for developing cardiovascular disease. I'm excited to be working with them as I believe their patented salt can improve the well being of patients and consumers worldwide," said Dr. Shah.

MicroSalt® aims to revolutionize the food industry with its patented sodium microparticle, that delivers the full-flavour experience of salt with roughly half the sodium. MicroSalt®'s salt particles are approximately 100 times smaller than regular table salt, allowing them to rapidly dissolve, producing a large sensation of saltiness. MicroSalt® is all-natural, non-GMO, and Kosher.

"We're very excited appoint Dr. Shah as our Chief Medical Officer. His extensive experience in cardiology will help to ensure that the benefit of MicroSalt® for reducing sodium content in snack foods and meals is well understood by consumers looking to improve their diets and enjoy a healthier lifestyle," said Victor Hugo Manzanilla, CEO of MicroSalt®.  

About Salarius Ltd.

Salarius, is the developer and manufacturer of a proprietary low-sodium salt called MicroSalt®. We are passionate about improving peoples' lives with better-for-you snacks by taking the lead in the industry by providing the best low-sodium salt solution, based on the mechanical transformation of the salt particle itself. This solution is the only one that delivers real salt flavor because it is salt. Our new patented technology produces salt crystals that are approximately one hundred times smaller than typical table salt, delivering a powerful saltiness as the micro-grains dissolve in the mouth, with approximately 50% less sodium consumption. Additionally, the ultra-small particle size enhances product adhesion, which reduces waste and provides improved flavor consistency. MicroSalt® and SaltMe® are registered trademarks of MicroSalt Inc.

To learn more about MicroSalt please visit https://Salarius.co/. 

To learn more about SaltMe! snacks please visit https://saltme.com/.

Tekcapital owns 97.2% of the share capital of Salarius Ltd. and 87.1% of the share capital of MicroSalt Inc., its U.S. subsidiary.

About Tekcapital plc

Tekcapital creates value from investing in new, university-developed discoveries that can enhance people's lives and provides a range of technology transfer services to help organisations evaluate and commercialise new technologies. Tekcapital is quoted on the AIM market of the London Stock Exchange (AIM: symbol TEK) and is headquartered in the UK. For more information, please visit www.tekcapital.com.

LEI: 213800GOJTOV19FIFZ85

For further information, please contact:

Flagstaff Strategic and Investor Communications                                    +44 (0)207 129 1474

Tim Thompson/Andrea Seymour/Fergus Mellon        

This press release is for informational purposes only. The information herein does not constitute investment advice nor an offer to invest and may contain statements related to our future business and financial performance and future events or developments involving Salarius that may constitute forward-looking statements. These statements may be identified by words such as "expect," "look forward to," "anticipate" "intend," "plan," "believe," "seek," "estimate," "will," "project" or words of similar meaning. We may also make forward-looking statements in other reports, in presentations, in material delivered to customers, stakeholders and in press releases. In addition, our representatives may from time to time make oral forward-looking statements. Such statements may be based on the current expectations and certain assumptions of Salarius' and/or Tekcapital's management. Please note that these are subject to a number of risks, uncertainties and factors, including, but not limited to those described in various disclosures. Should one or more of these risks or uncertainties materialize, or should underlying expectations not occur or assumptions prove incorrect, actual results, performance or achievements of Salarius or Tekcapital may vary materially from those described explicitly or implicitly in the relevant forward-looking statement. Neither Salarius nor Tekcapital intends, nor assumes any obligation, to update or revise these forward-looking statements in light of developments which differ from those anticipated.